CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Innovent's Sintbilo Meets Primary Endpoint in Phase 3 Cholesterol Trial

By Public Technologies
  • Innovent Biologics today reported its Phase 3 CREDIT-5 trial of Sintbilo (tafolecimab) monotherapy met its primary endpoint.
  • The 198-participant Chinese study showed significant cholesterol reductions versus placebo over 12 weeks in patients with non-familial hypercholesterolemia and mixed hyperlipidemia.
  • Treatment showed favorable safety and tolerability, with no severe or serious treatment-emergent adverse events or new safety signals.
  • The company plans to seek a new indication in China, potentially expanding Sintbilo’s use as a first-line standalone treatment for hyperlipidemia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611081900PR_NEWS_USPR_____CN91141) on November 09, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk